Anticancer Drugs
The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myel...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Online |
| Мова: | Англійська |
| Опубліковано: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Предмети: | |
| Онлайн доступ: | 42571 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| _version_ | 1869530777254887424 |
|---|---|
| author | O’Boyle, Niamh M Meegan, Mary J |
| author_browse | Meegan, Mary J O’Boyle, Niamh M |
| author_facet | O’Boyle, Niamh M Meegan, Mary J |
| author_sort | O’Boyle, Niamh M |
| collection | Directory of Open Access Books |
| description | The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients. |
| format | Online |
| id | doab-20.500.12854ir-40955 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-409552024-04-05T12:39:54Z Anticancer Drugs O’Boyle, Niamh M Meegan, Mary J QD1-999 Q1-390 graphene oxide indole androgens cyclooxygenase-2 cyclooxygenase-1 heteropolysaccharide drug conjugation drug delivery ellipticine chemical linker oesophageal cancer antiproliferative activity topoisomerase II ?-lactam DSD antibody topoisomerase inhibitors magnetic targeting cisplatin resistance steroidogenesis [18F]FDG PET/CT heterocyclic chemistry dehydroepiandrosterone antimitotic 3-vinylazetidin-2-ones glioblastoma and cancer therapy intestinal mucositis Combretastatin A-4 metabolism anti-cancer drugs maghemite COX-1 inhibitor anticancer CYP17A1 conjugate and hybrid drugs inflammation snticancer drugs P450c17 tumorigenesis cisplatin biomarker profiling cancer drug design tubulin cytochrome P450 5-fluorouracil prostate cancer abiraterone NCI screen radiation cancer immunotherapy microtubule targeted drugs cancer treatment resistance thema EDItEUR::P Mathematics and Science::PN Chemistry The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients. 2021-02-11T08:14:55Z 2021-02-11T08:14:55Z 2019-12-09 11:49:15 2019 book 42571 9783039215867 9783039215874 https://directory.doabooks.org/handle/20.500.12854/40955 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/1662 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03921-587-4 10.3390/books978-3-03921-587-4 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039215867 9783039215874 214 open access |
| spellingShingle | QD1-999 Q1-390 graphene oxide indole androgens cyclooxygenase-2 cyclooxygenase-1 heteropolysaccharide drug conjugation drug delivery ellipticine chemical linker oesophageal cancer antiproliferative activity topoisomerase II ?-lactam DSD antibody topoisomerase inhibitors magnetic targeting cisplatin resistance steroidogenesis [18F]FDG PET/CT heterocyclic chemistry dehydroepiandrosterone antimitotic 3-vinylazetidin-2-ones glioblastoma and cancer therapy intestinal mucositis Combretastatin A-4 metabolism anti-cancer drugs maghemite COX-1 inhibitor anticancer CYP17A1 conjugate and hybrid drugs inflammation snticancer drugs P450c17 tumorigenesis cisplatin biomarker profiling cancer drug design tubulin cytochrome P450 5-fluorouracil prostate cancer abiraterone NCI screen radiation cancer immunotherapy microtubule targeted drugs cancer treatment resistance thema EDItEUR::P Mathematics and Science::PN Chemistry O’Boyle, Niamh M Meegan, Mary J Anticancer Drugs |
| title | Anticancer Drugs |
| title_full | Anticancer Drugs |
| title_fullStr | Anticancer Drugs |
| title_full_unstemmed | Anticancer Drugs |
| title_short | Anticancer Drugs |
| title_sort | anticancer drugs |
| topic | QD1-999 Q1-390 graphene oxide indole androgens cyclooxygenase-2 cyclooxygenase-1 heteropolysaccharide drug conjugation drug delivery ellipticine chemical linker oesophageal cancer antiproliferative activity topoisomerase II ?-lactam DSD antibody topoisomerase inhibitors magnetic targeting cisplatin resistance steroidogenesis [18F]FDG PET/CT heterocyclic chemistry dehydroepiandrosterone antimitotic 3-vinylazetidin-2-ones glioblastoma and cancer therapy intestinal mucositis Combretastatin A-4 metabolism anti-cancer drugs maghemite COX-1 inhibitor anticancer CYP17A1 conjugate and hybrid drugs inflammation snticancer drugs P450c17 tumorigenesis cisplatin biomarker profiling cancer drug design tubulin cytochrome P450 5-fluorouracil prostate cancer abiraterone NCI screen radiation cancer immunotherapy microtubule targeted drugs cancer treatment resistance thema EDItEUR::P Mathematics and Science::PN Chemistry |
| topic_facet | QD1-999 Q1-390 graphene oxide indole androgens cyclooxygenase-2 cyclooxygenase-1 heteropolysaccharide drug conjugation drug delivery ellipticine chemical linker oesophageal cancer antiproliferative activity topoisomerase II ?-lactam DSD antibody topoisomerase inhibitors magnetic targeting cisplatin resistance steroidogenesis [18F]FDG PET/CT heterocyclic chemistry dehydroepiandrosterone antimitotic 3-vinylazetidin-2-ones glioblastoma and cancer therapy intestinal mucositis Combretastatin A-4 metabolism anti-cancer drugs maghemite COX-1 inhibitor anticancer CYP17A1 conjugate and hybrid drugs inflammation snticancer drugs P450c17 tumorigenesis cisplatin biomarker profiling cancer drug design tubulin cytochrome P450 5-fluorouracil prostate cancer abiraterone NCI screen radiation cancer immunotherapy microtubule targeted drugs cancer treatment resistance thema EDItEUR::P Mathematics and Science::PN Chemistry |
| url | 42571 |
| work_keys_str_mv | AT oboyleniamhm anticancerdrugs AT meeganmaryj anticancerdrugs |